Avicanna (TSE:AVCN) has released an update.
Avicanna Inc., a biopharmaceutical company, has been granted a US patent for its innovative topical cannabinoid technology designed to treat musculoskeletal inflammation and pain. The patent underscores the technology’s potential to deliver pain relief effectively while minimizing side effects typically associated with oral medications. Clinical studies have shown patient-reported improvements in symptoms and quality of life, validating the technology’s efficacy.
For further insights into TSE:AVCN stock, check out TipRanks’ Stock Analysis page.
